Clinical characteristics of male recipients undergoing transplantation from HLA-identical female sibling donors (F-to-M cohort) (n = 768)
| Patient variable . | N . | (%) . |
|---|---|---|
| Recipient age in y, median (range) | 44 (18-72) | |
| ≥50 | 303 | 39.5 |
| Diagnosis | ||
| Leukemia | 496 | 64.6 |
| Myelodysplastic syndrome | 99 | 12.9 |
| Lymphoma | 72 | 9.4 |
| Aplastic anemia | 42 | 5.5 |
| Adult T-cell leukemia/lymphoma | 34 | 4.4 |
| Myeloproliferative neoplasms | 20 | 2.6 |
| Others | 5 | 0.7 |
| Performance status | ||
| 0-1 | 724 | 94.3 |
| 2-4 | 44 | 5.7 |
| ABO mismatch | ||
| Match | 466 | 60.7 |
| Major | 132 | 17.2 |
| Minor | 128 | 16.7 |
| Major minor | 42 | 5.5 |
| Conditioning | ||
| Myeloablative | 547 | 71.2 |
| Reduced intensity | 221 | 28.8 |
| Source of stem cells | ||
| BM | 245 | 31.9 |
| PB | 522 | 68.0 |
| BM + PB | 1 | 0.1 |
| GVHD prophylaxis | ||
| Cyclosporine based | 598 | 77.9 |
| Cyclosporine + MTX | 552 | |
| Cyclosporine + MMF | 18 | |
| Cyclosporine + corticosteroid | 4 | |
| Others | 24 | |
| Tacrolimus-based | 160 | 20.8 |
| Tacrolimus + MTX | 142 | |
| Tacrolimus + MMF | 6 | |
| Tacrolimus + corticosteroid | 1 | |
| Others | 11 | |
| Missing | 10 | 1.3 |
| Years of transplantation | ||
| 2001-2010 | 124 | 16.1 |
| 2011-2019 | 644 | 83.9 |
| Patient variable . | N . | (%) . |
|---|---|---|
| Recipient age in y, median (range) | 44 (18-72) | |
| ≥50 | 303 | 39.5 |
| Diagnosis | ||
| Leukemia | 496 | 64.6 |
| Myelodysplastic syndrome | 99 | 12.9 |
| Lymphoma | 72 | 9.4 |
| Aplastic anemia | 42 | 5.5 |
| Adult T-cell leukemia/lymphoma | 34 | 4.4 |
| Myeloproliferative neoplasms | 20 | 2.6 |
| Others | 5 | 0.7 |
| Performance status | ||
| 0-1 | 724 | 94.3 |
| 2-4 | 44 | 5.7 |
| ABO mismatch | ||
| Match | 466 | 60.7 |
| Major | 132 | 17.2 |
| Minor | 128 | 16.7 |
| Major minor | 42 | 5.5 |
| Conditioning | ||
| Myeloablative | 547 | 71.2 |
| Reduced intensity | 221 | 28.8 |
| Source of stem cells | ||
| BM | 245 | 31.9 |
| PB | 522 | 68.0 |
| BM + PB | 1 | 0.1 |
| GVHD prophylaxis | ||
| Cyclosporine based | 598 | 77.9 |
| Cyclosporine + MTX | 552 | |
| Cyclosporine + MMF | 18 | |
| Cyclosporine + corticosteroid | 4 | |
| Others | 24 | |
| Tacrolimus-based | 160 | 20.8 |
| Tacrolimus + MTX | 142 | |
| Tacrolimus + MMF | 6 | |
| Tacrolimus + corticosteroid | 1 | |
| Others | 11 | |
| Missing | 10 | 1.3 |
| Years of transplantation | ||
| 2001-2010 | 124 | 16.1 |
| 2011-2019 | 644 | 83.9 |
F-to-M cohort indicates hematopoietic cell transplantation of male recipients with HLA-identical female sibling donors.
BM, bone marrow; MMF, mycophenolate mofetil; MTX, methotrexate; PB, peripheral blood.